Key facts
- Grow Group’s last known valuation is $68.7M (Dec 2023).
- It has raised $22.1M; the latest was Later Stage VC in Jan 2025.
- Notable investors include Triple Crown Ventures.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Grow Group
- ·The full record, as it builds
Funding rounds
No funding rounds for Grow Group are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Grow Group
Operator of a medical cannabis company intended to develop medicines and improve global patient access to those medicines. The company bridges the gap between current medical cannabis tools, processes, and practices and those that are generally deemed acceptable by the established pharmaceutical community, enabling medical cannabis producers to produce cost-effective medicines with ease.
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2017
- Employees
- 12
- Website
- growgroup.org/
- Ownership
- Privately Held (backing)
Grow Group doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Grow Group shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Grow Group in its N-PORT filings yet. We sweep new filings monthly.